Skip to main content

Dr. Céline Grunenwald implanted the 75th patient of the ASCENT ASD study at Nantes University Hospital CHU. This is one of the four centers in France and over 20 centers in the United States currently enrolling patients in the reSept ASD Occluder ongoing pivotal study.

“Transcatheter interventions are minimally invasive for patients compared to open-heart surgery. They enable faster recovery and return to normality,” explained Dr. Grunenwald, pediatric cardiologist specializing in transcatheter interventions at CHU Nantes. “A transcatheter device that helps preserve the heart’s natural structure may keep other transcatheter options open for the future. This could enable a virtuous circle of less invasive treatments in the life of a young patient born with a heart defect.”

The reSept ASD occluder is the first transcatheter septal occluder with a metal-free frame for atrial septal defect closure. Designed with long-term treatment in mind, the reSept ASD Occluder’s frame is made of fabric patches connected by bioresorbable filaments. It aims to maintain a low and more natural profile in the heart, compared to devices with a metal frame.

“We are delighted to see that patient’s enrolment in the trial is progressing well on both sides of the Atlantic,” said Laurent Grandidier, atHeart Medical CEO. “Thanks to these patients, their families and their clinicians, we are able to build a growing body of evidence for an evolved way to treat atrial septal defects.”

Please follow the links, for further information on the ASCENT ASD study and on ASDs.